SEC Filings

Form 424B3
ZOMEDICA PHARMACEUTICALS CORP. filed this Form 424B3 on 08/09/2018
Document Outline
Entire Document (619.2 KB)
Subdocument 1 - 424B3 - FORM 424B3
Page 1 - Filed pursuant to Rule 424(b)(3)
Page 2 - UNITED STATES
Page 3 - Zomedica Pharmaceuticals Corporation
Page 4 - PART I FINANCIAL INFORMATION
Page 5 - Zomedica Pharmaceuticals Corp.
Page 6 - Zomedica Pharmaceuticals Corp.
Page 7 - Zomedica Pharmaceuticals Corp.
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - Issued and outstanding common stock:
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - Item 2. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Page 21 - N/A
Page 22 - MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
Page 23 - Revenue
Page 24 - Critical Accounting Policies and Significant Judgments and Estimates
Page 25 - Translation of Foreign Currencies
Page 26 - Results of Operations
Page 27 - Cash Flows
Page 28 - Operating Activities
Page 29 - Liquidity and Capital Resources
Page 30 - Off Balance Sheet Arrangements
Page 31 - Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Page 32 - PART II OTHER INFORMATION
Page 33 - We are substantially dependent on the success of our lead product candidates, and cannot be certain
Page 34 - Our product candidates will face significant competition and may be unable to compete effectively.
Page 35 - Development of product candidates for use in companion animal health is an inherently expensive, tim
Page 36 - We will rely on third parties to conduct certain portions of our development activities. If these th
Page 37 - Risks Related to Intellectual Property
Page 38 - Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Page 39 - SIGNATURES
Page 40 - EXHIBIT INDEX